Cardiometabolic Disorders News

DALLAS — In this Healio video exclusive, Michael S. Irwig, MD, discusses how gender-confirming hormone therapy may affect obesity and cardiometabolic health.

DALLAS — New data presented at ObesityWeek demonstrate an encouraging early profile of an investigational dual GLP-1/GIP receptor agonist in healthy adults, according to a speaker at ObesityWeek.

DALLAS — Use of body composition or waist circumference was not superior to BMI to evaluate the presence of elevated blood pressure in adults undergoing a behavioral weight-loss intervention, according to data presented at ObesityWeek.

DALLAS — In this Healio video exclusive, Fatima Cody Stanford, MD, MPH, MPA, MBA, FAAP, FACP, FAHA, FAMWA, FTOS, discusses cultural competency with regard to obesity care.

The 2023 Cardiometabolic Health Congress will return in-person to Boston with the latest updates spanning all aspects of cardiometabolic health, including CVD, diabetes, kidney disease, lipid and lifestyle management and obesity.

NEW ORLEANS — In this video exclusive, Valerie Montgomery Rice, MD, president and CEO of Morehouse School of Medicine, talks about implications for medical education of the recent Supreme Court decision limiting affirmative action.

DALLAS — People with rare monogenic forms of obesity may reduce their risk for metabolic syndrome with setmelanotide therapy, according to research presented at ObesityWeek.

Higher initial glucose levels and increasing BMI over time could serve as predictors of progression from prediabetes to type 2 diabetes for children and adolescents, according to findings published in the Journal of the Endocrine Society.

Novo Nordisk has ended a clinical trial evaluating the impact of semaglutide on kidney function after the results from an interim analysis met certain pre-specified criteria, according to a company press release. To protect the integrity of the trial, Novo Nordisk will remain blinded to the results until the trial is completed, likely during the first half of 2024, according to the release. 

Children and adolescents with a high polygenic risk score for polycystic ovary syndrome tend to have a higher BMI and are more likely to develop obesity, according to study data.